IL-6 and MYC collaborate in plasma cell tumor formation in mice
- 4 March 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (9), 1746-1754
- https://doi.org/10.1182/blood-2009-08-237941
Abstract
Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-Ld-IL6, that encodes human IL-6 under control of the major histocompatibility complex H2-Ld promoter: strain C.H2-Ld-IL6. These mice are prone to PCT, but tumor development is incomplete with long latencies (∼ 40% PCT at 12 months of age). To generate a more robust mouse model of IL-6–dependent PCN, we intercrossed strain C.H2-Ld-IL6 with strains C.iMycEμ or C.iMycCα, 2 interrelated gene-insertion models of the chromosomal T(12;15) translocation causing deregulated expression of Myc in mouse PCT. Deregulation of MYC is also a prominent feature of human PCN. We found that double-transgenic C.H2-Ld-IL6/iMycEμ and C.H2-Ld-IL6/iMycCα mice develop PCT with full penetrance (100% tumor incidence) and short latencies (3-6 months). The mouse tumors mimic molecular hallmarks of their human tumor counterparts, including elevated IL-6/Stat3/Bcl-XL signaling. The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL-6 in treatment and prevention of human PCNs.Keywords
This publication has 49 references indexed in Scilit:
- Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative ComponentMayo Clinic Proceedings, 2009
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myelomaExperimental Cell Research, 2009
- SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKBlood, 2009
- Peroxisome Proliferator-Activated Receptor γ Overexpression Suppresses Growth and Induces Apoptosis in Human Multiple Myeloma CellsClinical Cancer Research, 2008
- AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor developmentThe Journal of Experimental Medicine, 2008
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple MyelomaClinical Cancer Research, 2007
- Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinasesOncogene, 2007
- INTERLEUKIN-6: From Basic Science to Medicine—40 Years in ImmunologyAnnual Review of Immunology, 2005
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999